Pipeline Progress vs. Profit Pain: Siemens Healthineers Stock Sinks as AI Milestones Fail to Sway Skeptics

Despite six new FDA approvals for radiology AI, Siemens Healthineers stock languishes near a 52-week low as weak diagnostics sales and a downgraded 2026 outlook overshadow innovation.

Siemens Healthineers notched six new U.S. regulatory clearances for artificial-intelligence systems designed to speed up radiology workflows and streamline hospital operations. Yet the stock continues to wallow near its 52-week low, a stark reminder that innovation headlines cannot mask a struggling core business.

The German medtech company’s shares closed at €33.59 on Friday, shedding 1.35% and leaving it just a hair above the recent trough of €33.50. The year-to-date loss now stands at 24.41%, and the 12-month decline is steeper still. The sell-off accelerated after Deutsche Bank trimmed its price target from €42 to €38, maintaining a “Hold” rating, as analyst Falko Friedrichs questioned the achievability of the company’s own 2026 profit forecast.

Diagnostics drag undercuts the AI story

The real weight on the equity is operational. Disappointing fiscal second-quarter numbers and a downgraded profit outlook for 2026 have shattered investor confidence. The diagnostics segment is the primary culprit. Weaker sales in China, combined with margin pressure from that market, continue to depress overall results. Even with the imaging and precision therapy divisions performing steadily — they are considered the bedrock of the group’s industrial quality — the diagnostics albatross is proving tough to shake.

Against that backdrop, the six FDA nods for AI tools look like a long-term strategic win that offers no short-term remedy. The cleared systems target radiology — a department where hospitals face intense cost pressure, making automation and faster scan interpretation genuinely valuable. Siemens Healthineers is positioning artificial intelligence at the centre of its digital-medtech pitch. But as one analyst noted, the market is not buying the story until the numbers improve.

What could change the view — and what won’t

Two events in May might eventually nudge the operating picture. A World Health Organization webinar next week will discuss fairness in AI-driven healthcare technologies, a field where the company’s digital portfolio could find policy tailwinds. And a World Bank roadshow in Tübingen is set to outline reformed procurement quality criteria, potentially opening new international tender opportunities for German medtech players. Neither, however, offers an immediate fix.

For now, the technical picture dominates. If the share price breaches support at €33, further losses are likely. On the upside, the revised Deutsche Bank target of €38 caps any near-term rally. The FDA clearances bolster the strategic narrative, but the stock needs proof in the profit-and-loss statement before it can attract fresh buying interest.